Men's Health News

RSS

VIVUS announces divestiture of MUSE to Meda

VIVUS, Inc. today announced that it has entered into an asset purchase agreement with Meda - an international specialty pharma company - for MUSE®, transurethral alprostadil, for the treatment of erectile dysfunction (ED). Under the agreement, Meda will acquire the MUSE assets including the United States and foreign MUSE patents, existing inventory and the manufacturing facility located in Lakewood, New Jersey.

4 Oct 2010

Prostate cancer mortality rate declines among American men: AHRQ

American men with prostate cancer were 45 percent less likely to die from the disease in 2006 than they were in 1999, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

4 Oct 2010

Meda announces acquisition of global rights to erectile dysfunction product MUSE

Meda today announced the acquisition of global rights to MUSE (transurethral alprostadil), a well established product for the treatment of erectile dysfunction.

4 Oct 2010

Osteoporosis common but underestimated in old men: Study

According to the latest research osteoporosis a diseases common in women that makes bones brittle and easily breakable with age also affects men. The study suggests that this debilitating condition is often overlooked in elderly Australian men.

3 Oct 2010

Men may connect strongly to publicity campaigns about depression and suicide

A recent study revealed that men might connect strongly to publicity campaigns about depression and suicide, particularly when they have options for anonymous help. In Regensburg, Germany, a two-year intervention campaign resulted in a marked drop in male suicides.

30 Sep 2010

Radical prostatectomy increases survival rate in prostate cancer patients: Study

In the largest, most modern, single-institution study of its kind, Mayo Clinic urologists mined a long-term data registry for survival rates of patients who underwent radical prostatectomy for localized prostate cancer. The findings are being presented at the North Central Section of the American Urological Association's 84th Annual Meeting in Chicago.

30 Sep 2010

Medivation and Astellas commence MDV3100 second Phase 3 clinical trial in advanced prostate cancer

Medivation, Inc. and Astellas Pharma Inc. today announced treatment of the first patient in a second Phase 3 clinical trial of the investigational drug MDV3100, which expands the Phase 3 development of the novel, triple-acting oral androgen receptor antagonist into an earlier-stage patient population. Known as PREVAIL, the trial will evaluate MDV3100 in men with advanced prostate cancer who have not yet received chemotherapy. Initiation of the PREVAIL trial triggers a milestone payment to Medivation under its collaboration agreement with Astellas.

29 Sep 2010

Most men unaware of breast cancer risk

A study, published in the October issue of the American Journal of Nursing (AJN), revealed that nearly 80% of men are unaware of their breast cancer risk despite having a family history of the disease. One hundred percent of respondents also reported that their healthcare provider did not discuss the disease with them.

29 Sep 2010

New predictive test to identify aggressive prostate cancer

S. Mark Redwood, M.D., chief of the Department of Urology at Sinai Hospital, is using a state-of-the-art predictive prostate cancer test called Prostate Px+ to better understand the aggressiveness of each individual patient's cancer and how best to treat it.

29 Sep 2010

Researchers find radical prostatectomy provides high survival rates

In one of the first studies to focus exclusively on the outcomes after treatment for patients with high-risk prostate cancer researchers have found that surgery provides high survival rates.

28 Sep 2010

Pfizer ceases SUN 1120 Phase 3 trial of SUTENT in men with CRPC

Pfizer Inc. announced today the discontinuation of the SUN 1120 Phase 3 trial evaluating SUTENT (sunitinib malate) in combination with prednisone for men with advanced castration-resistant prostate cancer that had progressed despite treatment with a docetaxel-based chemotherapy regimen. During a scheduled interim analysis, an independent Data Monitoring Committee found that the combination of sunitinib with prednisone was unlikely to improve overall survival when compared to prednisone alone.

28 Sep 2010

Depression and anxiety disorders common in loved ones of breast cancer patients: Study

Earlier studies have shown that women living with breast cancer are at a risk of depression but new studies have shown that their partners are at a similar risk. The study looked at more than a million men enrolled in a nationwide Danish health registry followed for 13 years.

28 Sep 2010

OncoGenex initiates OGX-427 Phase 2 trial for metastatic prostate cancer

OncoGenex Pharmaceuticals, Inc. announced today the initiation of a randomized, controlled, investigator sponsored Phase 2 trial of OGX-427 in men with metastatic prostate cancer.

27 Sep 2010

Comic books to educate young men about testicular cancer

Comic books may help to educate young men and their partners about testicular cancer and its early symptoms and encourage them to do more self-screening, according to Ryerson University School of Fashion professor and comic book artist David Brame.

24 Sep 2010

Many antisocial boys may have malfunctioning brains

Antisocial boys who abuse drugs, break laws, and act recklessly are not just "bad" kids. Many of these boys may have malfunctioning brains, according to a new study by researchers at the University of Colorado School of Medicine.

24 Sep 2010

Radiotherapy Centers of Georgia hosts motorcycle ride for prostate cancer awareness

Come ride with the thrill of fresh air in your face. This ride supports prostate cancer awareness, one of the leading killers of men in the state of Georgia. According to the American Cancer Society, Georgia ranks 6th in highest estimated deaths caused by prostate cancer; this is a serious concern for the state and for Radiotherapy Centers of Georgia, a center of excellence in treatment for prostate cancer.

24 Sep 2010

Male partners of women with breast cancer at increased risk of developing mood disorders

A new analysis finds that men whose partners have breast cancer are at increased risk of developing mood disorders that are so severe that they warrant hospitalization. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that clinicians should address the mental health of cancer patients' loved ones.

23 Sep 2010

Results of custirsen Phase 2 trial for advanced prostate cancer published in Journal of Clinical Oncology

OncoGenex Pharmaceuticals, Inc. announced today publication of results from a randomized Phase 2 trial in the Journal of Clinical Oncology. The trial results showed a survival benefit with the investigational agent OGX-011/TV1011 (custirsen) in patients with advanced prostate cancer. The median overall survival for patients who were treated with custirsen plus first-line docetaxel/prednisone was 23.8 months compared to 16.9 months for patients treated with docetaxel/prednisone alone.

22 Sep 2010

Gen-Probe submits PMA to FDA for PROGENSA PCA3 assay

Gen-Probe announced today that the Company has submitted a Premarket Approval Application (PMA) to the US Food and Drug Administration (FDA) for its PROGENSA® PCA3 assay, a new molecular test that may help determine the need for repeat biopsies in men suspected of having prostate cancer.

22 Sep 2010

Prostate cancer - TRAIL is worth a trial

One of the human body's protective mechanisms initiated by the TRAIL protein is massively altered in prostate cancer cells - yet the same protein seems to improve the survival prospects of patients. These outstanding results of a cooperative venture between the Clinical Program on Urological Tumours at the Medical University of Vienna and Harvard Medical School, USA, have just been published. They show that the TRAIL protein opens up the prospect to a more accurate prediction of the disease's course, as well as the opportunity to identify a new intervention point for innovative therapies in advanced prostate cancer.

21 Sep 2010